PRRT and theragnostic applications with PSMA-targeted radiopharmaceuticals, in particular with 177Lu-PSMA 617, are experiencing growing interest in oncology, especially for the management of patients with castration-resistant prostate cancer [101]. Here, FOLH1 is linked to prostate cancer.